Asad Haider

Stock Analyst at Goldman Sachs

(2.52)
# 2,421
Out of 5,042 analysts
11
Total ratings
100%
Success rate
9.68%
Average return

Stocks Rated by Asad Haider

Johnson & Johnson
Oct 9, 2025
Maintains: Buy
Price Target: $186$212
Current: $190.40
Upside: +11.34%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $17.71
Upside: -4.01%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $37.26
Upside: +12.72%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $42.24
Upside: -10.04%
NewAmsterdam Pharma Company
Jul 17, 2025
Initiates: Neutral
Price Target: $27
Current: $35.72
Upside: -24.41%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $105.66
Upside: +4.11%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892$888
Current: $825.45
Upside: +7.58%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $227.99
Upside: -14.91%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67$55
Current: $43.83
Upside: +25.48%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32$25
Current: $24.76
Upside: +0.97%